Type I Hypersensitivity Completed Phase 2 Trials for Tezepelumab (DB15090)

Also known as: Immediate Hypersensitivity / Hypersensitivity, Immediate / Immediate Type Hypersensitivity / Immediate hypersensitivity reaction / Immediate hypersensitivity reactions / Allergen-mediated IgE Allergy / Immediate hypersensitivity (disorder) / Hypersensitivity type I / Hypersensitivity type I NOS / Immunoglobulin E-mediated allergic disorder (disorder)

DBCOND0030618 (Type I Hypersensitivity)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03688074Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)Treatment